Merck KGaA and Intrexon entered into an exclusive strategic collaboration and license agreement to develop and commercialize chimeric antigen receptor T-cell (CAR T) cancer therapies. According to Belen Garijo, president and CEO of the Merck's biopharmaceutical business, the collaboration with Intrexon underlies the focus of Merck on innovation, and enhances its R&D technology portfolio in immuno-oncology. "Moreover, it showcases our commitment to developing therapies that have the potential to significantly evolve the way cancer is treated," he added.